Ishares Msci Spain ETF vs ImmunityBio Inc. Common Stock — how do they compare? Ishares Msci Spain ETF trades at $57.83 (market cap $2.36B), while ImmunityBio Inc. Common Stock trades at $10.01 (market cap $10.33B). The key difference: ImmunityBio Inc. Common Stock is far larger — about 4.4× Ishares Msci Spain ETF's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Ishares Msci Spain ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and ImmunityBio Inc. Common Stock for 0 Days on average.
| EWP | IBRX | |
|---|---|---|
Market Cap | $2.36B | $10.33B |
Volume | 297,635 | 11,745,198 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $11.55 |
52-Week Low | $48.33 | $1.98 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $10.79B |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →